Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Authors
  • Depatureaux, Agnès
  • Charpentier, Charlotte
  • Collin, Gilles
  • Leoz, Marie
  • Descamps, Diane
  • Vessière, Aurélia
  • Damond, Florence
  • Rousset, Dominique
  • Brun-Vézinet, Françoise
  • Plantier, Jean-Christophe
Type
Published Article
Journal
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Publication Date
Sep 01, 2010
Volume
54
Issue
9
Pages
4016–4019
Identifiers
DOI: 10.1128/AAC.00100-10
PMID: 20547806
Source
Medline
License
Unknown

Abstract

We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC(50)s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.

Report this publication

Statistics

Seen <100 times